BNTC Benitec Biopharma
- 6.8600
- +0.1400+2.08%
Benitec Biopharma News
JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $10 to $16.
Benitec Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 128.57% JMP Securities $10 → $16 Maintains Market Outperform 02/15/2024 42.86% JMP Securities $
Benitec Biopharma's $40 Million Equity Financing Deal
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Top Midday Gainers
AGBA Group (AGBA) agreed to merge with artificial intelligence-driven social video platform Triller. The financial-services company said the value of the proposed business combination would be $4 bill
Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?
Thursday, Benitec Biopharma Inc (NASDAQ:BNTC) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study's first subject (Subject 1) treated in the BB
CGC, GENE and HOLO Among Mid-day Movers
Express News | Benitec Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29%
Benitec Biopharma Showcases Encouraging Clinical Trial Results
Trending Stocks Today: Tian Ruixiang Soars 227.94% Pre-Market
April 18th - US stocks trending pre-market: Gainers: $Tian Ruixiang(TIRX.US)$ soars 227.94% to $1.59 with a turnover of $36.99 million. $AGBA Group(AGBA.US)$ surges 212.5% to $1.25 with a turnover of
Market-Moving News for April 18th
BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to
Why Benitec Biopharma Is Rising In Pre-market?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. The market value of their outstanding shares is at $3.5 million. SINTX Techs (NASDAQ:SINT)
Top Premarket Gainers
Tian Ruixiang Holdings (TIRX) shares nearly tripled Thursday premarket following a 7.7% increase in the previous session. MicroCloud Hologram (HOLO) shares surged 42% pre-bell after Wednesday's 5.5% d
Express News | Benitec Biopharma Shares Are Trading Higher. The Company Announced a $40 Million Oversubscribed Private Placement Financing and Reported Interim Clinical Data for the First OPMD Subject Treated With BB-301 in Its Phase 1b/2a Study
Express News | Benitec Biopharma Inc: Regarding Bb-301 Safety Profile Observed to Date, No Serious Adverse Events Have Been Observed for Two Subjects
Express News | Benitec Biopharma Inc: Bb-301 Has Been Granted Orphan Drug Designation by US FDA and EMA Committee for Orphan Medicinal Products (Comp)
Express News | Benitec Biopharma Inc: Bb-301 Facilitated Improvements Across Multiple Measures of Swallowing Function in First Phase 1B/2a Clinical Study Subject
Express News | Benitec Biopharma Reports Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study; Says 'BB-301 Facilitated Improvements Across Multiple Measures of Swallowing Function in the First Phase 1b/2a Clinical Study Subject as
Express News | Benitec Biopharma: First Efficacy Signals Demonstrated for Gene Therapy Under Development for Oculopharyngeal Muscular Dystrophy (Opmd)
Analysis
Price Target
No Data
